Leucomycin

Leucomycin (Kitasamycin) is an orally active macrolide antibiotic produced by Streptomyces kitasatoensis. Leucomycin has broad-spectrum antibacterial activities against gram-positive and gram-negative bacteria, mycoplasma, leptospira, spirochaetes, rickettsiae and some larger viruses[1][2][3][4][5][6][7].

Product Specifications

CAS Number

[1392-21-8]

Product Name Alternative

Kitasamycin

UNSPSC

12352005

Hazard Statement

H302

Target

Antibiotic; Bacterial

Type

Natural Products

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/leucomycin.html

Solubility

DMSO : 110 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

[Leucomycin]

Precautions

H302

References & Citations

[1]PACHTMAN EA, et al. Leucomycin; a new antibiotic. Am J Pharm Sci Support Public Health. 1958 Oct;130 (10) :342-4.|[2]Vézina C, et al. Biosynthesis of kitasamycin (leucomycin) by leucine analog-resistant mutants of Streptomyces kitasatoensis. Antimicrob Agents Chemother. 1979 May;15 (5) :738-46.|[3]La T, et al. Testing the efficacy of kitasamycin for use in the control and treatment of swine dysentery in experimentally infected pigs. Aust Vet J. 2019 Sep 17.|[4]Hassan AB, et al. Pharmacokinetics and tissue residues of kitasamycin in healthy and diseased broilers. Dtsch Tierarztl Wochenschr. 1990 Aug;97 (8) :315-7.|[5]Iwata K, et al. Studies on the in vitro Antibacterial Activity of Leucomycin[J]. The Journal of Antibiotics, Series A, 1962, 15 (6) : 258-265.|[6]Kondo M, et al. Maridomycin, a new macrolide antibiotic. 3. In vitro and in vivo antibacterial activity. J Antibiot (Tokyo) . 1973 Apr;26 (4) :206-14. |[7]Liu G, et al. Quantitative analysis of impurities in leucomycin bulk drugs and tablets: A high performance liquid chromatography-charged aerosol detection method and its conversion to ultraviolet detection method. J Pharm Biomed Anal. 2021 Aug 5;202:114148.